Company Xenetic Biosciences Inc Other OTC
Equities
US9840151073
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
Mar. 21 | Xenetic Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Mar. 18 | CLS Therapeutics Discloses its Views on Xenetic Biosciences | CI |
Business Summary
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Cell-based Therapeutics
100.0
%
| 2 | 100.0 % | 3 | 100.0 % | +48.80% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 2 | 100.0 % | 3 | 100.0 % | +48.80% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 58 | 16-07-10 | |
James F. Parslow
DFI | Director of Finance/CFO | 59 | 17-04-02 |
Curtis Lockshin
CTO | Chief Tech/Sci/R&D Officer | 64 | 14-02-28 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 58 | 16-07-10 | |
Moshe Mizrahy
BRD | Director/Board Member | 71 | - |
Adam Logal
CHM | Chairman | 46 | 17-08-13 |
Director/Board Member | 56 | 03-12-31 | |
Roger Kornberg
BRD | Director/Board Member | 77 | 16-02-28 |
Director/Board Member | 72 | 14-01-22 | |
Director/Board Member | 54 | 19-07-18 | |
Director/Board Member | 68 | 17-08-13 | |
Director/Board Member | 55 | 19-09-24 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 0 | 1,804,394 | 0 | 0 | 80.81 % |
Stock B | 1 | 1,543,385 | 1,247,242 ( 80.81 %) | 2,701 ( 0.1750 %) | |
Stock C | 0 | 970,000 | 0 | 0 |
Company contact information
Sector
1st Jan change | Capi. | |
---|---|---|
-2.73% | 103B | |
+1.42% | 95.28B | |
+1.46% | 22.15B | |
-15.88% | 21.02B | |
-8.58% | 18.15B | |
-38.74% | 16.73B | |
-12.92% | 16.05B | |
+5.05% | 13.68B | |
+33.49% | 12.17B |
- Stock Market
- Equities
- XBIO Stock
- Stock
- Company Xenetic Biosciences Inc